SynthesisPharmacoEconomics2021

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.

Martijn J H G Simons et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.